Published online Mar 14, 2017. doi: 10.3748/wjg.v23.i10.1780
Peer-review started: September 19, 2016
First decision: October 20, 2016
Revised: November 6, 2016
Accepted: December 2, 2016
Article in press: December 2, 2016
Published online: March 14, 2017
Processing time: 176 Days and 21.4 Hours
To compare the expression levels of interleukin (IL)-6 in colorectal cancer (CRC) tissues and adjacent non-cancerous tissues, and analyse the correlation of IL-6 expression with the clinicopathological parameters of CRC.
Fifty CRC tissue specimens and 50 matched adjacent mucosa specimens were collected. The expression of IL-6 in these clinical samples was examined by immunohistochemical staining. The correlation between IL-6 expression and clinicopathological parameters was assessed by statistical analysis.
IL-6 expression was significantly elevated in CRC tissues compared with noncancerous tissues (P < 0.001). IL-6 expression was positively correlated with tumour TNM stage (P < 0.001), but a negative correlation was detected between IL-6 expression and tumor histological differentiation in CRC (P < 0.05). Furthermore, IL-6 expression was associated with invasion depth and lymph node metastasis in CRC.
IL-6 might be a useful marker for predicting a poor prognosis in patients with CRC and might be used as a potential therapeutic target in CRC.
Core tip: Colorectal cancer (CRC) is the fourth leading cause of cancer-related death worldwide. Previous studies have demonstrated that interleukin (IL)-6 is a critical tumor promoter during early CRC tumorigenesis. However, there have been few studies regarding the expression of IL-6 and its prognostic role in CRC. Therefore, we explored the correlation between the expression of IL-6 and the clinicopathological features in CRC. To the best of our knowledge, this is the first analysis of the expression of IL-6 in resected CRC samples using immunohistochemistry combined with biostatistics. The results showed that the expression of IL-6 was correlated with tumour TNM stage and histological differentiation. Furthermore, IL-6 in tumour cells showed stronger immunoreactivity as tumour cells invaded deeply. These data indicated that IL-6 might be used as a potential therapeutic target in patients with CRC.